Based on structure-activity relationships of the angiostatic ␤-sheet-forming peptide anginex, we have designed a mimetic, 6DBF7, which inhibits angiogenesis and tumor growth in mice. 6DBF7 is composed of a ␤-sheet-inducing dibenzofuran (DBF)-turn mimetic and two short key amino acid sequences from anginex. This novel antiangiogenic molecule is more effective in vivo than parent anginex. In a mouse xenograft model for ovarian carcinoma, 6DBF7 is observed to reduce tumor growth by up to 80%. It is suggested that the activity is based on antiangiogenesis, because in vitro tube formation is inhibited, and because treatment of tumor-bearing mice led to a significant reduction in microvessel density within the tumor. This partial peptide mimetic is the first endothelial cell-specific molecule designed as a substitute for an angiostatic inhibitory peptide.
1 growth and EC adhesion (4, 5) . Targeting ECs as an anti-tumor treatment is attractive primarily because ECs are more accessible than are other cells to pharmacologic agents delivered via the blood, and ECs are genetically stable and are not easily mutated into drug-resistant variants. Most antiangiogenic agents have been discovered by identifying endogenous molecules (primarily proteins) that inhibit EC growth. This traditional approach has produced a number of antiangiogenics, such as platelet factor-4 (6), thrombospondin (7), interferon-␥ inducible protein-10 (8), angiostatin (9) , endostatin and restin (2, 10) , and bactericidal permeability-increasing protein (11) .
Numerous angiostatic compounds have been identified, many of which are currently in various phases of clinical cancer trials (cancertrials.nci.nih.gov). Although a number of compounds have shown promise in the clinic, no major breakthroughs have been reported using antiangiogenic agents as stand-alone therapies. This underscores the need for more and better angiostatic compounds for use as stand-alone therapies or in combination with conventional therapies. Moreover, some angiogenesis inhibitors have been shown to be ineffective or to cause diverse and multiple unwanted biological side effects (12) . This latter phenomenon was, to some extent, expected as many of these endogenous angiostatic proteins are pleiotropic; i.e. they are involved in several biological processes. Often these functions are found to arise from separate sites on the molecule and thus can be separated using smaller segments or domains of a given protein (13) . This relates to the search for new antiangiogenic agents, which is aimed at improving specificity, reducing the therapeutic dosage, and minimizing molecular size with a small molecule antiangiogenic agent or antiangiogenic protein mimetic. This is one of the main goals among structural biologists and pharmaceutical chemists working to produce novel antiangiogenic agents. For the design of small molecule mimetics of antiangiogenic proteins, the identification of specific, functionally key amino acid residues and their spatial relationships is crucial. Nevertheless, structureactivity relationships for antiangiogenic proteins are sorely needed, and even the analysis of high-resolution molecular structures of a number of antiangiogenic proteins, e.g. endostatin (14) , platelet factor-4 (15) , and bactericidal permeabilityincreasing protein (16) , has yet to provide this information.
Recently, we reported the design of the anginex peptide, a cytokine-like ␤-sheet-forming peptide 33-mer (17) , which is a potent inhibitor of angiogenesis (1) and tumor growth (18 -20) . Anginex is more effective at inhibiting EC growth than platelet factor-4 and several other well known angiogenesis inhibitors such as angiostatin, endostatin, AGM-1470, and thrombospondin-1 (1) . This peptide 33-mer acts by specifically blocking adhesion and migration of angiogenically activated ECs, leading to apoptosis and ultimately to inhibition of angiogenesis in vitro and in vivo and inhibition of human tumor growth by up to ϳ80% in various models (18 -20) . Anginex is an amphipathic ␤-sheet-forming peptide (17, 21) , and because of the relatively small size of anginex, a complete structure-activity relationship is easier to perform than with larger known anti-angiogenic proteins like those mentioned above. Here we report for the first time the design of a partial peptide mimetic of anginex that was based on the identification of functionally key residues and the conformation responsible for the antiangiogenic activity of anginex.
MATERIALS AND METHODS
Peptide Synthesis-Peptides were synthesized using a Milligen/Biosearch 9600 peptide solid-phase synthesizer using Fmoc chemistry. Lyophilized crude peptides were purified by preparative reversed-phase HPLC on a C18 column with an elution gradient of 0 -60% acetonitrile with 0.1% trifluoroacetic acid in water. The purity and composition of the peptides were verified by HPLC (Beckman Model 6300) analysis of amino acid composition of hydrolysates prepared by treating the peptides under argon in 6 N HCl for 24 h at 110°C. The amino acid sequences of peptides were confirmed by N-terminal sequencing and mass spectrometry.
Synthesis of DBF Analogs-Unexceptional phases of solid-phase peptide synthesis were carried out on an ABI 431 peptide synthesizer (Applied Biosystems, Inc.) using Fmoc methodology and (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate/N-hydroxybenzotriazole as coupling reagents. Fmoc-DBF-CO 2 H was prepared by slight modification of the reported method (22) . In this ninestep synthesis, the intermediates and final product were characterized by TLC and 1 H NMR with GC-low resolution mass spectrometry, 13 (23) . The remaining couplings required for production of 2DBF7 through 11DBF7 were carried out using (benzotriazol-1-yloxy)-tris(dimethylamino)phosphonium hexafluorophosphate/N-hydroxybenzotriazole conditions on the peptide synthesizer. After the final Fmoc deprotection, each of the DBF peptides was released from the resin with simultaneous removal of all acidolyzable trityl and tert-butyl side-chain-protecting groups using Reagent K (24). A Rink amide or similar resin was used to provide the primary amide form of the Cterminal Asp 24 unit. Lyophilized crude peptides were purified by HPLC as described above. Purity and composition of the peptides were verified by analytical HPLC matrix-assisted laser desorption ionization mass spectrometry using a Hewlett-Packard G2025A system and sinapinic acid as matrix and by analysis of amino acid composition of hydrolysates (6 N HCl at 110°C for 24 h under argon).
NMR Spectroscopy-For NMR measurements, freeze-dried DBF analogs were dissolved in water:Me 2 SO:dodecylphosphocholine mixture. Peptide concentration was 3 mM. pH was adjusted to pH 5.7 by adding l quantities of NaOD or HCl to the peptide sample. NMR spectra were acquired on a Varian UNITY Plus-600 NMR spectrometer at 25°C. Two-dimensional homonuclear total correlation spectroscopy with DIPSI (decoupling in the presence of scalar interactions) (25) spinlock (mixing time, 80 ms) was used to identify spin systems. Two-dimensional nuclear Overhauser effect spectroscopy experiments (26) were performed for sequential assignments and conformational analysis. WATERGATE (27, 28) was used to attenuate the water resonance. Spectra were collected as 256 -512 t1 experiments, each with 2,048 complex data points over a spectral width of 6 kHz in both dimensions with the carrier placed on the water resonance. 16 scans were timeaveraged per t1 experiment. Data were processed directly on the spectrometer using VNMR (Varian, Inc., Palo Alto, CA) or NMRPipe (29) on an SGI work station.
Structural Modeling-Analysis of NOE growth curves indicated that backbone-to-backbone interproton NOEs were normally maximum at about 200 ms. Interproton distance constraints were derived from NOEs assigned in 1 H nuclear Overhauser effect spectra acquired with mixing times of 100 ms. NOEs were classified as strong, medium, weak, or very weak corresponding to upper bound distance constraints of 2.3, 2.8, 3.5, and 4.5 Å, respectively. The lower bound restraint between nonbonded protons was set to 1.8 Å. Pseudo-atom corrections were added to the upper bound distance constraints where appropriate, and an 0.5-Å correction was added to the upper bound for NOEs involving methyl protons. Hydrogen bond constraints were identified from the pattern of sequential and interstrand NOEs involving NH and C␣H protons together with evidence of slow amide proton-solvent exchange.
Each hydrogen bond identified was defined using two distance constraints: r NH-O ϭ 1.8 -2.5 Å and r N-O ϭ 1.8 -2.5 Å.
Derived internuclear distance constraints were used in calculating structures for 6DBF7 by using X-PLOR software (30) . The molecule was created, and a template coordinate set was generated by using the Template software routine. The ab initio simulated annealing protocol was then used. The simulated annealing procedure ran high temperature dynamics (3,000 K for 120 ps) and then cooled down to 100 K in 50-K steps with 1.5 ps molecular dynamics at each step. Powell minimization was performed at 100 K for 1,000 steps. Structure refinement was done based on simulated annealing starting at 1,000 K and ending at 100 K. Final structures were subjected to the X-PLOR Accept software routine with the violation threshold for NOEs of 0.5 Å and dihedral angles of 5°. Angles, bond lengths, or impropers were not allowed to deviate from ideal geometry more than 5°, 0.05 Å, and 5°, respectively. Structures were superimposed using the BIOSYM INSIGHT viewer (Molecular Simulations, Inc.) and were analyzed using X-PLOR analysis routines.
Cells, Cultures, and Reagents-Human umbilical vein-derived endothelial cells (HUVECs) were harvested from normal human umbilical cords by perfusion with 0.125% trypsin/EDTA. Harvested HUVECs were cultured in gelatin-coated tissue culture flasks and subcultured 1:3 once a week in culture medium (RPMI 1640 with 20% human serum supplemented with 2 mM glutamine, 100 units/ml penicillin, and 0.1 mg/ml streptomycin). Bovine capillary endothelial (BCE) cells were kindly provided by Dr. M. Furie (State University of New York, Stony Brook, NY) and were cultured in fibronectin-coated tissue culture flasks in RPMI 1640 medium containing 10% fetal calf serum, glutamine, and antibiotics.
Proliferation Measurement-EC proliferation was measured using a [ 3 H]thymidine incorporation assay. Proliferation of bFGF-stimulated (10 ng/ml) HUVEC cultures was measured by quantification of [ 3 H]thymidine incorporation. Proliferation is expressed as mean counts/min of quadruplicate cultures in three independent experiments (Ϯ S.E.). ECs were seeded at 5,000 cells/well in flat-bottomed tissue culture plates and grown for 3 days in culture medium in the absence or presence of regulators. During the last 6 h of the assay, the culture was pulsed with 0.5 Ci of [methyl-
3 H]thymidine/well. HUVECs were harvested from normal human umbilical cords by perfusion with 0.125% trypsin/EDTA. Harvested HUVECs were cultured in gelatin-coated tissue culture flasks and subcultured 1:3 once a week in culture medium (RPMI 1640 with 20% human serum supplemented with 2 mM glutamine and 100 units/ml penicillin and 0.1 mg/ml streptomycin).
In Vitro Angiogenesis Assay-Sprouting and tube formation of BCEs were studied using Cytodex-3 beads overgrown with BCEs in a threedimensional collagen gel (Vitrogen-100, Collagen Corp., Fremont, CA) as described by van der Schaft et al. (31) . Following gelation, culture medium containing 20 ng/ml bFGF, with or without anginex or DBF analogs, was applied on top of the gel. After 24 h of cell culture at 37°C, photographs were made as shown in Fig. 3 . The amount of sprouting in each well (i.e. the total length of the sprouts) was quantified by the computer program NIH Image. To quantify differences in sprouting and tube formation, statistical analysis was performed using the MannWhitney U test.
Tumor Model Studies in Athymic (Nude) Mice-In all studies, female athymic nude mice (nu/nu, 5-6 weeks old) were used. These mice were purchased from the National Cancer Institute and allowed to acclimatize to local conditions for at least 1 week. Animals were given water and standard chow ad libitum and were kept on a 12-h light/dark cycle. All experiments were approved by the University of Minnesota Research Animal Resources ethical committee. Mice were randomized and split into three groups: 1) human serum albumin (10 mg/kg/day), 2) anginex (10 mg/kg/day), and 3) DBF analog (10 mg/kg/day). Compounds were diluted in 100 mM SDS and administered using osmotic minipumps (Durect, Cupertino, CA). Exponentially grown MA148 human ovarian carcinoma cells, kindly provided by Prof. Ramakrishnan (18) , were cultured in RPMI 1640 medium (Invitrogen). This medium was supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Cellgro, Mediatech, Washington, DC) at 37°C and 5% CO 2 . 100 l of this tumor cell suspension (2 ϫ 10 7 cells/ml) was then injected subcutaneously into the right flank of each mouse. Pumps were implanted into the left flanks of the mice for subcutaneous administration of this compound over a 28-day treatment span.
Two variants of this model were used: prevention and intervention. For the prevention variant, treatment was initiated at the time of inoculation with MA148 cells. For the intervention variant, tumors were allowed to grow to an average size of 50 mm 3 (usually day 7 post-inoculation) before treatment was initiated. With either variant, the animals were randomized prior to the initiation of treatment. Treatment was administered via osmotic mini-pumps (Durect, Cupertino, CA), which were implanted subcutaneously in the left flanks of the mice. Concentrated solutions of anginex or DBF analogs were formulated such that the 28-day treatment period would be covered by implantation of a single pump. In each study, control groups of animals were administered either PBS or PBS containing human serum albumin. Tumor growth curves were found to be virtually identical in either of these control cases.
Tumor volume was determined by measuring the diameters of tumors using calipers (Scienceware, Pequannock, NJ) using the equation for the volume of a spheroid: (a 2 ϫ b ϫ )/6, where "a" is the width and "b" the length of the tumor. Measurements were performed two or three times per week. At the conclusion of an experiment, tumor weights were also taken following excision of the tumors from euthanized animals. Tumor weights correlated well with tumor volumes calculated in this way.
Immunohistochemistry-Immunohistochemistry was used to assess microvessel density and the extent of total cell apoptosis. Tumor tissue was embedded in tissue-freezing medium (Miles, Inc., Elkart, IN) and shock-frozen in liquid nitrogen. Sections of tissue (10-m thickness) were prepared for immunohistochemical analysis. For this, tissue sections were brought to room temperature, air-dried overnight, and then fixed in acetone for 10 min. Slides were allowed to air-dry for at least 30 min and were washed three times for 5 min each in phosphate-buffered saline (PBS, pH 7.4). Samples were then blocked with PBS containing 0.1% bovine serum albumin and 3% human serum albumin for at least 30 min at room temperature in a humidified box. Samples were subsequently incubated with phycoerythrin-conjugated monoclonal antibody to CD31 (PECAM-1) in a 1:50 dilution (Pharmingen, San Diego, CA) to stain for microvessel density. After a 1-h incubation at room temperature, slides were washed with PBS and immediately imaged using an Olympus BX-60 fluorescence microscope at 200ϫ magnification.
To assess the extent of total cell apoptosis, tissue sections were stained by using the TUNEL (terminal deoxyribonucleotidyl transferase-mediated dUTP-nick-end labeling) assay, which was performed according to the manufacturer's instructions (in situ cell death detection kit, fluorescein; TUNEL, Roche Applied Science). Digital images were stored and processed using Adobe Photoshop (Adobe, Inc., Mountain View, CA). Quantification of microvessel density, the rate of proliferation, and total cell apoptosis were determined as described earlier (32) . Statistical analysis was performed using the Student's t test.
Toxicity Assays-As an indirect measurement of general toxicity, body weights of mice were monitored twice weekly, using a digital balance (Ohaus; Florham, NJ). To determine hematocrit and creatinine levels, blood samples were extracted by tail vein bleedings 1 day after terminating treatment, and blood was collected in heparinized microhematocrit capillary tubes (Fisher). For hematocrit levels, samples were spun down for 10 min in a micro-hematocrit centrifuge (ClayAdams), and the amount of hematocrit was determined using an international microcapillary reader (IEC; Needham, MA). To obtain creatinine levels, a kit was purchased from Sigma and used according to the manufacturer's instructions.
RESULTS
Design of a Partial Peptide Mimetic-For input into designing the mimetic, we first performed structure-activity studies on anginex. Working with this relatively small peptide 33-mer allowed for a thorough assessment of functionally key residues by using alanine scanning and walk-through variants. The relative anti-proliferative effect of alanine-substituted analogs 50 values from dose response curves; only IC 50 values for dodecapeptides with significant activity relative to anginex are given. The overall fold for anginex (3 ␤-strands with 2 turns) is shown with functionally key residues boxed (B). The parent DBF analog is depicted with the introduction of the scaffold and the two functionally key ␤-strand sequences from anginex (C).
of anginex against ECs is plotted in Fig. 1A . Residues that demonstrate the most significant drop in the ability of anginex to inhibit EC proliferation are hydrophobic residues within the first two ␤-strands: Ile 3 , Leu 5 , Val 7 , Leu 11 , and Ile 20 . Conformationally, these functionally key hydrophobic residues all lie on the same face of the amphipathic anti-parallel ␤-sheet (17, The compound had no effect on the assay. 21 ). Also shown in Fig. 1A are anti-proliferation activities of eight walk-through dodecapeptides that successively sample segments of the anginex sequence, shifting three residues in each peptide. Only three walk-through peptides (IC 50 values listed at the right) demonstrate any significant anti-proliferative activity relative to parent anginex. As with results from alanine scanning, these peptides also encompass ␤-strands 1 and 2. Based on these results, we concluded that antiangiogenic activity is localized within ␤-strands 1 and 2 and that residues in turns 1 and 2 and ␤-strand 3 are functionally dispensable. For orientation, the ␤-strand alignment for anginex is depicted in Fig. 1B ; portions of the molecule containing the key sequences are boxed. Using this information, we designed the DBF-series of partial peptide mimetics in which ␤-strand 3 and turn 2 of anginex were omitted and a DBF ␤-turn mimetic (33, 34) was used in place of residues Phe 12 to Lys 19 . The DBF ␤-turn mimetic was used to maintain the bioactive ␤-sheet conformation of anginex (21) . The parent DBF-based compound depicted in Fig. 1C is called 11DBF7, where numbers at the left and right of DBF refer to the number of amino acid residues in the N-and C-terminal strands, respectively, from anginex. To identify the shortest sequences required for bioactivity, a series of N-and C-terminal deletion variants of 11DBF7 was made as listed in Table I .
␤-Sheet Structure Is Preserved in DBF Analogs-We used NMR spectroscopy to investigate whether ␤-sheet conformation was preserved in DBF analogs. Analogs 11DBF7 and 6DBF7 (that has more equivalent ␤-strand lengths) were the focus of this structural study. Because of their limited water solubility and the desire to mimic a membrane-like environment, these compounds were investigated in dodecylphosphocholine micelles. At the millimolar concentrations required for NMR work, 11DBF7 gave overlapping resonances that made spectral analysis ambiguous, whereas 6DBF7 gave excellent NMR spectra that allowed complete structural analysis. NOEs and coupling constants diagnostic of anti-parallel ␤-sheet conformation were readily identified and used in computational modeling. The superimposed 28 lowest energy structures ( Fig.  2A) have a backbone root mean square deviation value (N-and C-terminal residues excluded) of 0.11 Å. Additional structural statistics are given in Table II . A simplified illustration of this folding pattern is shown in Fig. 2B , which highlights residues on both hydrophobic and hydrophilic surfaces of the ␤-sheet. In this orientation of the molecule, the dibenzofuran moiety is lying on edge. Notice also that two aliphatic hydrophobic residues, leucine (Leu 11 ) and isoleucine (Ile 20 ) from anginex, are packed against the phenyls of the DBF group in 6DBF7 (Fig.  2B ). In effect, this sets up and helps to stabilize the ␤-sheet fold (22) . Based on this structural information, we concluded that other DBF analogs would fold similarly, albeit to various extents depending on the lengths of the two strands; i.e. strands of equal length are expected to be better able to form ␤-sheets. DBF Analogs Retain Antiangiogenic Activity-In EC proliferation assays, we demonstrated that 11DBF7, as well as a number of shorter analogs including 6DBF7, are effective at inhibiting EC growth. Exemplary dose-response curves for all xDBF7 analogs are given in Fig. 3A , and IC 50 values for all analogs are listed in Table I . Even though DBF analogs are less active than parent anginex, this may be explained in part by their having a decreased number of residues. Some of the analogs are missing residues identified by alanine scanning as being functionally important (e.g. Leu 5 and Ile 3 ). Nonetheless, a number of these shorter analogs remain reasonably active, and it appears that the N-terminal hexapeptide SVQMKL and C-terminal hexapeptide IIVKLN are most essential for maintaining antiangiogenic activity.
Angiostatic potential was further demonstrated in the collagen gel-based sprout formation assay (21) . Whereas control cultures show numerous sprouts (Fig. 3B) , treatment with 6DBF7 (Fig. 3C), 11DBF7 (Fig. 3D), and anginex (Fig. 3E) all demonstrate highly reduced sprouting. These effects are quantified in Table I . In general, reducing the number of amino acid 
FIG. 3. Bioactivity of DBF analogs in in vitro assays.
The antiproliferative effects of some DBF analogs on bFGF-activated ECs are plotted as dose-response curves (A). To assess the antiangiogenic potential of these DBF analogs, sprouting and tube formation were studied using Cytodex-3 beads overgrown with BCE in a three-dimensional collagen gel. residues in the ␤-strands leads to reduced inhibition of sprout formation comparable with results from the EC proliferation assay. Nonetheless, some analogs were active in this assay, and one of the shortest analogs, 6DBF7, did demonstrate a significant inhibitory effect on tube formation. The kinetics of inhibition using DBF analogs, moreover, were the same as those observed with parent anginex (data not shown).
11DBF7 and 6DBF7 Inhibit Tumor Growth in Mice-Because our immediate interest in an antiangiogenic agent is in the area of tumor biology, we assessed the in vivo efficacy of two of the most active in vitro DBF analogs, 11DBF7 and 6DBF7, in the MA148 xenograft ovarian carcinoma tumor model in athymic mice (18 -20) . Our initial experiments using this model administered the parent analog, 11DBF7, subcutaneously via mini-pumps implanted at the time of inoculation with the tumor cell line. This prevention model demonstrated that treatment of tumor-bearing animals with 11DBF7 resulted in inhibition of tumor growth. Surprisingly, 11DBF7 functioned, on average, slightly better than anginex by reducing tumor volume by up to 80% relative to tumors from control animals (Fig. 4A) .
In further experiments, we initiated treatment 7 days after inoculation with tumor cells to allow establishment of tumors prior to the start of treatment. Using this protocol, anginex and 11DBF7 were found to inhibit tumor growth by up to 70% during the course of treatment (Fig. 4B) . At the end of the 4-week administration period (day 35), the rate of tumor growth began to increase but remained at about 50% 10 days post-treatment (not shown) when animals were sacrificed for analysis of tumor tissue. Interestingly, the smaller analog, 6DBF7, was even more effective than anginex or 11DBF7 at inhibiting the growth of tumors (Fig. 4B) . The reason for this is unclear but may be related to improved bioavailability of 6DBF7.
Antiangiogenic potential in vivo was demonstrated immunohistochemically by staining tumor cross-sections from treated animals with fluorescently labeled anti-CD31 antibody to identify blood vessels. As shown in Fig. 4 , C-F, and quantified in Table III , vessel density relative to control (Fig. 4C ) was significantly reduced by treatment with anginex ( Fig. 4D) , 11DBF7 (Fig. 4E ), or 6DBF7 (Fig. 4F ). These antiangiogenic compounds had a significant effect as well on vessel architecture, demonstrating a drop in the number of end points, branch points, and vessel length (Table III) . In addition, antiangiogenic treatment also reduced the rate of proliferation of tumor cells as determined by immunohistochemical staining of proliferating cell nuclear antigen in cryosections of tumors (Table  III) . As a result of angiogenic inhibition, the number of apoptotic tumor cells increased from 311 Ϯ 103 in the control to 620 Ϯ 146 and 851 Ϯ 162 in anginex-and 6DBF7-treated animals, respectively.
In all in vivo experiments, treatment with anginex, 11DBF7, and 6DBF7 did not show any sign of toxicity as assessed by unaltered behavior and normal weight gain during experiments (see inserts to Fig. 4, A and B) . Moreover, hematocrit and creatinine levels in treated animals were normal relative to control, indicating the absence of toxicity to bone marrow and kidney, respectively. Upon autopsy, macro-and microscopic morphologies of internal organs were also observed to be normal within all experimental groups of animals.
DISCUSSION
Here we identified functionally key amino acid residues in the ␤-sheet-forming anginex peptide that promote its angiostatic activity, and using this structure-activity relationship information, we designed partial nonpeptidic ␤-sheet mimetics of anginex. Members of this novel class of DBF-based compounds are effective antiangiogenic agents both in vitro and in vivo. FIG. 4 . 6DBF7 inhibits tumor growth in mice. MA148 tumorbearing mice were treated with the optimal dose of anginex (10 mg/kg/ day) or equivalent doses of 11DBF7 or 6DBF7. Treatment was initiated at the time of inoculation with MA148 cells (A). An intervention study is shown where tumors were allowed to establish to a palpable size before treatment was initiated (B). In either study, control groups of animals were treated with PBS containing human serum albumin to control for protein content. Tumor volumes (A and B; for all groups n ϭ 11, Ϯ S.E.) are plotted as mm 3 versus days post-inoculation. The inserts in A and B show the body weight development of the mice during the study as a measurement of overall toxicity. Immunohistochemical analysis of microvessel density is shown (C-F). C represents the average number of microvessels in the tumor of a control-treated animal. Panels D, E, and F represent the average amount of vessel density staining on tumor tissue from anginex-, 11DBF7-, and 6DBF7-treated animals, respectively. Original magnification 200ϫ; scale bar ϭ 50 m. Moreover, the in vivo anti-tumor activity of one of these DBF mimetics, 6DBF7, is improved over that of the larger parent molecule, anginex. The ␤-sheet conformation in particular is crucial to the antiangiogenic activity of these DBF analogs just as it is for parent anginex peptide (17, 21) . 6DBF7 is shown here to fold as an amphipathic ␤-sheet with functionally key hydrophobic residues lying on the same face of the molecule. Interestingly, the crystal structure of VEGF complexed with an antiangiogenic peptide (Flt-1D2) (35) derived from one of its endothelial cellspecific tyrosine kinase receptors, Flt-1, indicates that functionally key segments of Flt-1D2 are located within its ␤-sheet domain. Moreover, one of the peptides derived from this domain, NITVTLKKFPL, inhibits angiogenesis through a non-VEGF binding mechanism, i.e. without binding to VEGF or without inhibiting the binding of VEGF to its receptors (36) . CD and NMR analyses indicate that this Flt-1 peptide 11-mer forms a stable extended ␤-strand structure in solution. In this conformation, the peptide would present N-terminal hydrophobic amino acid residues Ile-Val-Leu on the same face of the strand. This Ile-Val-Leu presentation pattern is also present in 6DBF7 (␤-strand 2) along with the cross-strand hydrophobic pattern Val-Met-Leu (␤-strand 1). Although the efficacy of the Flt-1 peptide is much less than that of 6DBF7, this structural/ compositional similarity between these two peptides suggests that, on the molecular level, the ␤-sheet structure of these molecules is pivotal to their activity (37) , which may suggest signaling through a common cellular receptor.
Known high-resolution molecular structures of many other antiangiogenic proteins (e.g. endostatin (14) , platelet factor-4 (15), tumor necrosis factor-␣ (38), bactericidal permeabilityincreasing protein (16) , and TSP-1 type 1 repeat (39)) are also structurally (antiparallel ␤-sheet) and compositionally (high incidence of hydrophobic and positively charged residues) similar to anginex and DBF mimetics. Although this observation may indicate an evolutionary structural link among a number of antiangiogenic proteins, the meaning of this commonality remains unclear because their mechanisms of action and cellular receptors could be different. To complicate matters further, few receptors reported to mediate the signal leading to angiostasis are definitive, and a number of antiangiogenic agents apparently can act on multiple receptors. For angiostatin, for example, three receptors on endothelial cells have been reported: ATP-synthase (40) and integrins ␣ v ␤ 3 and ␣ 9 ␤ 1 (41) . For endostatin, there are currently also at least three possibilities: a low affinity cell-surface glypican receptor along with a yet to be identified high affinity receptor (42) and an intercellular epitope (hTM3) in tropomyosin (43); and for another well known antiangiogenic protein, TSP-1, there are four identified receptors: syndecan, heparin sulfate proteoglycans, integrinassociated protein (reviewed in Ref. 12) , and its long known transmembrane receptor, CD36 (44, 45) .
Even with these uncertainties, the compositional and structural similarity noted among anginex, 6DBF7, and various antiangiogenic proteins and peptides may be used to further improve or optimize the efficacy of anginex peptide mimetics and in the design of additional novel therapeutic antiangiogenic agents. For the present, 6DBF7 appears to be one of the most potent antiangiogenic and anti-tumor agents known. This claim is supported by the observation that anginex is as potent as angiostatin and more potent than endostatin at inhibiting the growth of ovarian tumors in mice (18) . Therefore, based on the present comparison with anginex, 6DBF7 must also be more potent in vivo than endostatin or angiostatin. The design of 6DBF7 places us on the road to creating an actual small molecule pharmaceutical agent that could be used as an effective therapeutic against cancer as well as against other angiogenically related pathologic disorders like arthritis, restenosis, endometriosis, and diabetic retinopathy.
